ATE476657T1 - Vorhersage von letalität und detektion von schweren erkrankungen - Google Patents
Vorhersage von letalität und detektion von schweren erkrankungenInfo
- Publication number
- ATE476657T1 ATE476657T1 AT07761219T AT07761219T ATE476657T1 AT E476657 T1 ATE476657 T1 AT E476657T1 AT 07761219 T AT07761219 T AT 07761219T AT 07761219 T AT07761219 T AT 07761219T AT E476657 T1 ATE476657 T1 AT E476657T1
- Authority
- AT
- Austria
- Prior art keywords
- prediction
- detection
- lethality
- serious diseases
- hospital
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79435406P | 2006-04-24 | 2006-04-24 | |
US80036206P | 2006-05-15 | 2006-05-15 | |
US90460807P | 2007-03-02 | 2007-03-02 | |
PCT/US2007/067333 WO2007127749A2 (en) | 2006-04-24 | 2007-04-24 | Predicting mortality and detecting severe disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE476657T1 true ATE476657T1 (de) | 2010-08-15 |
Family
ID=38656334
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT10171764T ATE527544T1 (de) | 2006-04-24 | 2007-04-24 | Vorhersage von letalität und detektion von schweren erkrankungen |
AT07761219T ATE476657T1 (de) | 2006-04-24 | 2007-04-24 | Vorhersage von letalität und detektion von schweren erkrankungen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT10171764T ATE527544T1 (de) | 2006-04-24 | 2007-04-24 | Vorhersage von letalität und detektion von schweren erkrankungen |
Country Status (12)
Country | Link |
---|---|
US (7) | US7998683B2 (de) |
EP (5) | EP2010912B1 (de) |
JP (4) | JP5383480B2 (de) |
AT (2) | ATE527544T1 (de) |
AU (1) | AU2007244927B2 (de) |
CA (1) | CA2650201C (de) |
DE (1) | DE602007008224D1 (de) |
DK (3) | DK2386860T3 (de) |
ES (4) | ES2378314T3 (de) |
HK (3) | HK1164443A1 (de) |
PL (2) | PL2848938T3 (de) |
WO (1) | WO2007127749A2 (de) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
HUE039881T2 (hu) | 2002-05-09 | 2019-02-28 | Brigham & Womens Hospital Inc | 1L1RL-1, mint egy kardiovaszkuláris betegség-marker |
EP1731910A1 (de) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten |
ES2378314T3 (es) | 2006-04-24 | 2012-04-11 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de enfermedades graves. |
WO2007143295A2 (en) * | 2006-04-27 | 2007-12-13 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
WO2007130962A2 (en) | 2006-05-01 | 2007-11-15 | Critical Care Diagnostics, Inc. | Diagnosis of cardiovascular disease |
ES2723957T3 (es) * | 2006-05-02 | 2019-09-04 | Critical Care Diagnostics Inc | Procedimiento de selección de un tratamiento basado en el diagnóstico diferencial entre enfermedad pulmonar y cardiovascular |
CN101495517B (zh) * | 2006-05-25 | 2012-10-10 | 莫曼塔医药品有限公司 | 低分子量肝素及其用途 |
US11389080B2 (en) | 2007-11-28 | 2022-07-19 | Intervet Inc. | System and method for diagnosis of bovine diseases using auscultation analysis |
WO2009100907A1 (en) * | 2008-02-14 | 2009-08-20 | Dianeering Diagnostics Engineering And Research Gmbh | Means and methods for assessing the risk of patients presenting to emergency departments based on very low concentrations of troponin i or t or using a combination of markers |
EP2242494A4 (de) * | 2008-02-20 | 2013-01-02 | Momenta Pharmaceuticals Inc | Verfahren zur herstellung von heparinzusammensetzungen mit geringem molekulargewicht |
PL2827152T3 (pl) * | 2008-04-18 | 2016-12-30 | Rokowanie ryzyka głównych niekorzystnych zdarzeń sercowych | |
EP2141499A1 (de) * | 2008-07-02 | 2010-01-06 | Apoptec AG | COPD-Diagnose |
US9883799B2 (en) * | 2008-10-16 | 2018-02-06 | Fresenius Medical Care Holdings, Inc. | Method of identifying when a patient undergoing hemodialysis is at increased risk of death |
US20100099958A1 (en) * | 2008-10-16 | 2010-04-22 | Fresenius Medical Care Holdings Inc. | Method of identifying when a patient undergoing hemodialysis is at increased risk of death |
US10064580B2 (en) | 2008-11-07 | 2018-09-04 | Intervet Inc. | System and method for determining antibiotic effectiveness in respiratory diseased animals using auscultation analysis |
JP2012063139A (ja) * | 2008-12-15 | 2012-03-29 | Hokkaido Univ | 糖鎖分析による膵臓がんの診断方法 |
JP2012063140A (ja) * | 2008-12-15 | 2012-03-29 | Hokkaido Univ | 糖鎖分析による肺がんの診断方法 |
EP2480237A1 (de) * | 2009-09-23 | 2012-08-01 | Momenta Pharmaceuticals, Inc. | Behandlungsverfahren mit einer heparinzusammensetzung von geringem molekulargewicht |
EA201290311A1 (ru) * | 2009-11-13 | 2012-12-28 | БиДжи МЕДИСИН, ИНК. | Факторы риска и прогнозирование инфаркта миокарда |
CA2788760A1 (en) * | 2010-03-26 | 2011-09-29 | Pronota N.V. | Ltbp2 as a biomarker for renal dysfunction |
CA2795200C (en) * | 2010-04-09 | 2020-01-14 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
JP2011232164A (ja) * | 2010-04-27 | 2011-11-17 | Keio Gijuku | 肝臓疾患マーカー、その測定方法、装置及び医薬品の検定方法 |
US20110295613A1 (en) * | 2010-05-28 | 2011-12-01 | Martin Coyne | Inpatient utilization management system and method |
US20130302841A1 (en) * | 2010-11-01 | 2013-11-14 | B.R.A.H.M.S Gmbh | Prognosis and risk assessment of patients with non-specific complaints |
GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
WO2012075222A2 (en) | 2010-12-02 | 2012-06-07 | Fresenius Medical Care Holdings, Inc. | Method of identifying when a patient undergoing hemodialysis is at increased risk of death |
EP3605104B1 (de) | 2011-03-17 | 2021-09-15 | Critical Care Diagnostics, Inc. | Verfahren zur vorhersage des risikos eines negativen klinischen ergebnisses |
EP3173093B1 (de) | 2011-07-18 | 2018-12-05 | Critical Care Diagnostics, Inc. | Verfahren zur behandlung kardiovaskulärer erkrankungen und zur vorhersage der wirksamkeit einer bewegungstherapie |
US20130157290A1 (en) * | 2011-12-16 | 2013-06-20 | Yves Levy | Soluble st2 as a marker for disease |
EP3434260A1 (de) * | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Verfahren zur behandlung oder vorhersage des risikos des ereignisses von ventrikulärer tachyarrhythmie |
AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
SG11201501200XA (en) * | 2012-08-16 | 2015-04-29 | Critical Care Diagnostics Inc | Methods for predicting risk of developing hypertension |
CN111834009A (zh) | 2012-08-21 | 2020-10-27 | 重症监护诊断股份有限公司 | 多标记风险分层 |
MX362388B (es) | 2013-02-06 | 2019-01-15 | Geissler Companies Llc | Sistema y metodo para determinar la efectividad antibiotica en animales con enfermedades del sistema respiratorio usando un analisis de auscultacion. |
US20150199491A1 (en) | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
EP3198023B1 (de) | 2014-09-26 | 2020-04-22 | Somalogic, Inc. | Vorhersage eines kardiovaskulären risikoereignisses und verwendungen davon |
KR102064045B1 (ko) | 2014-10-29 | 2020-01-08 | 에프. 호프만-라 로슈 아게 | 사망 위험성을 예측하기 위한 바이오마커 |
JP7231326B2 (ja) | 2014-11-10 | 2023-03-01 | ジェネンテック, インコーポレイテッド | Il-33媒介性障害のための治療及び診断方法 |
US10093730B2 (en) | 2014-11-10 | 2018-10-09 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
CN106952043B (zh) * | 2017-03-23 | 2021-04-13 | 国家电网公司客户服务中心 | 一种计划停电敏感度评估方法和装置 |
CN108982871B (zh) * | 2018-07-19 | 2021-09-24 | 北京市心肺血管疾病研究所 | 血清sST2在小儿扩张型心肌病预后中的应用 |
MX2022011156A (es) | 2020-03-13 | 2022-10-13 | Genentech Inc | Anticuerpos anti-interleucina-33 y usos de estos. |
WO2023201054A1 (en) * | 2022-04-15 | 2023-10-19 | Memorial Sloan-Kettering Cancer Center | Multi-modal machine learning to determine risk stratification |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
US5206140A (en) * | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
JPH0731479Y2 (ja) | 1989-06-02 | 1995-07-19 | 内橋エステック株式会社 | 温度ヒューズ |
US5217899A (en) | 1990-08-24 | 1993-06-08 | The General Hospital Corporation | Cell stretching apparatus |
JP2665850B2 (ja) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | hBNPのC端を認識するモノクロ−ナル抗体 |
GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
JPH0731479A (ja) | 1993-02-23 | 1995-02-03 | Shinichi Tominaga | マウスst2lをコードするdna、該dnaの発現産物、該dnaを発現させることによる発現産物の製造方法 |
US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
AU7235296A (en) | 1996-08-23 | 1998-03-06 | Human Genome Sciences, Inc. | T1 receptor-like ligand ii |
JP2001513641A (ja) | 1997-02-28 | 2001-09-04 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | T1/st2−レセプターリガンド▲iii▼ |
DE19711932A1 (de) | 1997-03-21 | 1998-09-24 | Anne Katrin Dr Werenskiold | In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms |
EP1003501B9 (de) | 1997-04-02 | 2005-06-08 | The Brigham And Women's Hospital, Inc. | Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen |
JP5264026B2 (ja) | 1997-06-10 | 2013-08-14 | エルパス・インコーポレイテッド | 心疾患の早期発見のための方法 |
CA2304263C (en) | 1997-09-11 | 2008-07-29 | Shionogi & Co., Ltd. | Immunoassay method for bnp |
GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
GB9827348D0 (en) | 1998-12-12 | 1999-02-03 | Univ Leicester | Natriuretic peptide |
AU2055300A (en) | 1998-12-18 | 2000-07-03 | Scios Inc. | Methods for detection and use of differentially expressed genes in disease states |
AU5309600A (en) | 1999-06-02 | 2000-12-18 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
FR2795823B1 (fr) | 1999-07-01 | 2001-11-23 | Inst Nat Sante Rech Med | Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial |
EP1210117A2 (de) | 1999-08-24 | 2002-06-05 | Medicure International Inc. | Zusammensetzungen zur behandlung von kardiovaskularen krankheiten die pyridoxal-derivate und kardiovaskuläre mittel enthalten |
US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
WO2001070817A1 (fr) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant |
FR2807170B1 (fr) | 2000-03-30 | 2002-06-28 | Sipal | Charniere elastique a frottement reduit |
CA2388061A1 (en) | 2000-08-22 | 2002-02-28 | The Brigham And Women's Hospital, Inc | Diagnosis and treatment of cardiovascular conditions |
US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
US6537221B2 (en) | 2000-12-07 | 2003-03-25 | Koninklijke Philips Electronics, N.V. | Strain rate analysis in ultrasonic diagnostic images |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
DE60233301D1 (de) | 2001-05-04 | 2009-09-24 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
US6810284B1 (en) | 2001-11-21 | 2004-10-26 | Pacesetter, Inc. | Implantable cardiac stimulation system and method for monitoring diastolic function |
HUE039881T2 (hu) | 2002-05-09 | 2019-02-28 | Brigham & Womens Hospital Inc | 1L1RL-1, mint egy kardiovaszkuláris betegség-marker |
MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
AU2003239544A1 (en) * | 2002-05-24 | 2003-12-12 | Tularik Inc. | Amplification and overexpression of oncogenes |
US8263325B2 (en) * | 2002-11-15 | 2012-09-11 | Ottawa Heart Institute Research Corporation | Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis |
AU2003299441A1 (en) | 2002-12-19 | 2004-07-14 | Centre National De La Recherche Scientifique - Cnrs | Nf-hev compositions and methods of use |
US20040133079A1 (en) | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
US20040220155A1 (en) | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
WO2005043123A2 (en) | 2003-10-31 | 2005-05-12 | Queststar Medical, Inc. | System and apparatus for body fluid analysis using surface-textured optical materials |
CA2860272C (en) | 2003-11-26 | 2017-12-19 | Celera Corporation | Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof |
ES2381551T3 (es) | 2003-12-05 | 2012-05-29 | The Cleveland Clinic Foundation | Marcadores de riesgo para enfermedad cardiovascular |
US20050196817A1 (en) * | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
JP2005291899A (ja) * | 2004-03-31 | 2005-10-20 | Akira Matsumori | 心疾患の検査法 |
WO2006066095A1 (en) | 2004-12-17 | 2006-06-22 | Clearwater Systems Corporation | Method and apparatus for treating fluids |
WO2006077265A1 (en) | 2005-01-24 | 2006-07-27 | F. Hoffmann-La Roche Ag | The use of bnp-type peptides and anp-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload |
EP1731910A1 (de) | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten |
US20070021977A1 (en) * | 2005-07-19 | 2007-01-25 | Witt Biomedical Corporation | Automated system for capturing and archiving information to verify medical necessity of performing medical procedure |
JP4820192B2 (ja) | 2006-03-17 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | 急性冠症候群でのadamts13の測定と利用 |
ES2378314T3 (es) * | 2006-04-24 | 2012-04-11 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de enfermedades graves. |
WO2007143295A2 (en) | 2006-04-27 | 2007-12-13 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
WO2007130962A2 (en) | 2006-05-01 | 2007-11-15 | Critical Care Diagnostics, Inc. | Diagnosis of cardiovascular disease |
ES2723957T3 (es) | 2006-05-02 | 2019-09-04 | Critical Care Diagnostics Inc | Procedimiento de selección de un tratamiento basado en el diagnóstico diferencial entre enfermedad pulmonar y cardiovascular |
WO2007130627A2 (en) | 2006-05-04 | 2007-11-15 | The Brigham And Women's Hospital, Inc. | Il-33 in the treatment and diagnosis of diseases and disorders |
RU2312591C1 (ru) | 2006-06-14 | 2007-12-20 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией |
US20080233191A1 (en) | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
US20090111708A1 (en) | 2007-05-11 | 2009-04-30 | Seddon Johanna M | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
GB0713404D0 (en) | 2007-07-11 | 2007-08-22 | Integra Sp Ipr Ltd | Altio graph |
WO2009040133A1 (en) | 2007-09-26 | 2009-04-02 | Universitätsklinikum Heidelberg | Osteopontin as novel prognostic biomarker for heart failure |
FR2923029B1 (fr) | 2007-10-26 | 2009-11-20 | Minima | Lunettes de type sans entourage a branches filaires |
PL2827152T3 (pl) | 2008-04-18 | 2016-12-30 | Rokowanie ryzyka głównych niekorzystnych zdarzeń sercowych | |
WO2010054810A1 (en) | 2008-11-11 | 2010-05-20 | B.R.A.H.M.S Ag | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp |
EA201290311A1 (ru) | 2009-11-13 | 2012-12-28 | БиДжи МЕДИСИН, ИНК. | Факторы риска и прогнозирование инфаркта миокарда |
CA2795200C (en) | 2010-04-09 | 2020-01-14 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
US20130302841A1 (en) | 2010-11-01 | 2013-11-14 | B.R.A.H.M.S Gmbh | Prognosis and risk assessment of patients with non-specific complaints |
RU2452394C1 (ru) | 2010-11-09 | 2012-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет | Способ прогнозирования риска смерти больных хронической сердечной недостаточностью |
EP3605104B1 (de) | 2011-03-17 | 2021-09-15 | Critical Care Diagnostics, Inc. | Verfahren zur vorhersage des risikos eines negativen klinischen ergebnisses |
EP3173093B1 (de) | 2011-07-18 | 2018-12-05 | Critical Care Diagnostics, Inc. | Verfahren zur behandlung kardiovaskulärer erkrankungen und zur vorhersage der wirksamkeit einer bewegungstherapie |
EP3434260A1 (de) | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Verfahren zur behandlung oder vorhersage des risikos des ereignisses von ventrikulärer tachyarrhythmie |
SG11201501200XA (en) | 2012-08-16 | 2015-04-29 | Critical Care Diagnostics Inc | Methods for predicting risk of developing hypertension |
CN111834009A (zh) | 2012-08-21 | 2020-10-27 | 重症监护诊断股份有限公司 | 多标记风险分层 |
JP6178687B2 (ja) | 2013-09-27 | 2017-08-09 | 富士機械工業株式会社 | グラビア塗工装置 |
US20150199491A1 (en) | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
US9934249B2 (en) | 2014-06-03 | 2018-04-03 | Conduent Business Machines Services, Llc | Systems and methods for context-aware and personalized access to visualizations of road events |
USD800333S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
USD800332S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2007
- 2007-04-24 ES ES10171764T patent/ES2378314T3/es active Active
- 2007-04-24 DK DK11177461.8T patent/DK2386860T3/en active
- 2007-04-24 ES ES07761219T patent/ES2351623T3/es active Active
- 2007-04-24 PL PL14188319T patent/PL2848938T3/pl unknown
- 2007-04-24 WO PCT/US2007/067333 patent/WO2007127749A2/en active Application Filing
- 2007-04-24 AT AT10171764T patent/ATE527544T1/de active
- 2007-04-24 EP EP07761219A patent/EP2010912B1/de active Active
- 2007-04-24 EP EP11177461.8A patent/EP2386860B1/de not_active Not-in-force
- 2007-04-24 EP EP14188319.9A patent/EP2848938B1/de not_active Not-in-force
- 2007-04-24 DE DE602007008224T patent/DE602007008224D1/de active Active
- 2007-04-24 ES ES11177461.8T patent/ES2529618T3/es active Active
- 2007-04-24 ES ES14188319.9T patent/ES2646142T3/es active Active
- 2007-04-24 EP EP10171764A patent/EP2241888B1/de active Active
- 2007-04-24 EP EP17177530.7A patent/EP3255432B1/de not_active Not-in-force
- 2007-04-24 DK DK14188319.9T patent/DK2848938T3/da active
- 2007-04-24 PL PL11177461T patent/PL2386860T4/pl unknown
- 2007-04-24 AU AU2007244927A patent/AU2007244927B2/en not_active Ceased
- 2007-04-24 AT AT07761219T patent/ATE476657T1/de active
- 2007-04-24 JP JP2009507931A patent/JP5383480B2/ja not_active Expired - Fee Related
- 2007-04-24 DK DK10171764.3T patent/DK2241888T3/da active
- 2007-04-24 US US11/789,169 patent/US7998683B2/en active Active
- 2007-04-24 CA CA2650201A patent/CA2650201C/en not_active Expired - Fee Related
-
2011
- 2011-07-08 US US13/179,173 patent/US8617825B2/en active Active
- 2011-10-26 US US13/282,111 patent/US9568481B2/en active Active
-
2012
- 2012-04-26 JP JP2012100940A patent/JP5806165B2/ja active Active
- 2012-05-16 HK HK12104804.4A patent/HK1164443A1/xx not_active IP Right Cessation
-
2013
- 2013-03-07 US US13/787,975 patent/US9057733B2/en not_active Expired - Fee Related
-
2015
- 2015-09-03 JP JP2015173815A patent/JP6214604B2/ja active Active
- 2015-09-17 HK HK15109122.5A patent/HK1208724A1/xx not_active IP Right Cessation
- 2015-09-17 HK HK18107615.0A patent/HK1248311B/zh not_active IP Right Cessation
-
2017
- 2017-01-19 US US15/410,155 patent/US10067146B2/en active Active
- 2017-09-19 JP JP2017178945A patent/JP2017215347A/ja active Pending
-
2018
- 2018-08-13 US US16/101,939 patent/US11016103B2/en active Active
-
2021
- 2021-04-27 US US17/241,303 patent/US20210255200A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE476657T1 (de) | Vorhersage von letalität und detektion von schweren erkrankungen | |
Vijayan et al. | Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy | |
Patel et al. | Biomarkers for wound healing and their evaluation | |
Fan et al. | Diagnosing sepsis–The role of laboratory medicine | |
ATE554386T1 (de) | Verbesserte immunoassayverfahren | |
WO2010057184A3 (en) | Methods for detection of acute kidney injury in humans | |
DE602006018578D1 (de) | Diagnose- und prognoseverfahren von blasenkrebs. | |
JP2009501333A5 (de) | ||
Wijeratne et al. | Cell‐free plasma DNA as a prognostic marker in intensive treatment unit patients | |
Letendre et al. | Measurement of plasma cell‐free DNA concentrations in dogs with sepsis, trauma, and neoplasia | |
RU2008103988A (ru) | Способ диагностики рассеяного склероза | |
GB0524110D0 (en) | Biomarkers and methods for identification of agents useful in the treatment of affective disorders | |
DE602005022709D1 (de) | Quantifizierungsverfahren für die vegf isoformen einer biologischen probe | |
EP1930445A4 (de) | Kit und verfahren zum nachweis von urothelkarzinom | |
CY1112423T1 (el) | Αναλυτικη συσκευη μικροεπεξεργαστη μιας χρησης | |
Hou et al. | Branched DNA-based Alu quantitative assay for cell-free plasma DNA levels in patients with sepsis or systemic inflammatory response syndrome | |
EP1898215A4 (de) | Verfahren zum testen endokriner substanz in proben | |
AU2006228990A8 (en) | A method of diagnosis and treatment and agents useful for same | |
Clerico et al. | Biomarkers for sepsis: an unfinished journey | |
ATE426168T1 (de) | Verwendung von asc als marker fur kolorektalkarzinome | |
Wang et al. | An evaluation of aging measures: from biomarkers to clocks | |
Ajjimarungsi et al. | Clinical characteristics, outcomes, and predictors of leptospirosis in patients admitted to the medical intensive care unit: A retrospective analysis | |
WO2008035204A3 (en) | Prediction and prophylactic treatment of type 1 diabetes | |
ATE509270T1 (de) | Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung | |
de AB Cobra et al. | Cell-free deoxyribonucleic acid: a potential biomarker of chronic periprosthetic knee joint infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 2010912 Country of ref document: EP |